Świerzb – Rokowania, prognozy i postęp choroby

Świerzb
Rokowania, prognozy i postęp choroby

Świerzb (Scabies) jest powszechną chorobą skóry o globalnym zasięgu, dotykającą rocznie 150-200 milionów osób, szczególnie w populacjach o niskim statusie społeczno-ekonomicznym i w regionach tropikalnych. Choroba ta, często występująca u dzieci, wiąże się z ryzykiem powikłań bakteryjnych, takich jak zakażenia paciorkowcami grupy A i gronkowcem złocistym, które mogą prowadzić do zapalenia nerek, ostrej gorączki reumatycznej czy inwazyjnej posocznicy. Leczenie, obejmujące terapię pacjenta oraz jego bliskich, daje dobre rokowanie z oczekiwanym wyzdrowieniem w ciągu około dwóch tygodni. Skuteczność leczenia jest zróżnicowana – iwermektyna w pojedynczej dawce wykazuje wskaźnik wyleczenia 78,5%, a 10% maść siarkowa 59,5%. Niepowodzenia terapeutyczne wynikają często z błędnej diagnozy, nieprawidłowego stosowania leków, słabej penetracji preparatów w hiperkeratotycznej skórze lub reinfekcji od kontaktów.

Wprowadzenie do świerzbu (Scabies)

Świerzb (łac. Scabies) jest jedną z najczęstszych chorób skóry na świecie, dotykającą rocznie 150-200 milionów ludzi. Choroba ta występuje we wszystkich częściach świata, ze szczególnym nasileniem w populacjach o niskim statusie społeczno-ekonomicznym, zamieszkujących regiony tropikalne i subtropikalne. ¹ Warto podkreślić, że świerzb najczęściej dotyka dzieci z rodzin o niższym statusie społeczno-ekonomicznym, zwłaszcza w regionach o ograniczonych zasobach medycznych. ²

Przez długi czas świerzb był błędnie postrzegany jedynie jako pasożyt zewnętrzny wywołujący świąd. Jednak badania epidemiologiczne wskazują na znaczącą zachorowalność, a nawet śmiertelność związaną z tą inwazją pasożytniczą, głównie z powodu wtórnych zakażeń bakteryjnych. ¹ Obciążenie chorobą jest obecnie dobrze scharakteryzowane, w tym nadkażenia bakteryjne paciorkowcami grupy A i gronkowcem złocistym, które mogą prowadzić do zapalenia nerek, ostrej gorączki reumatycznej lub nawet śmiertelnej inwazyjnej posocznicy wtórnej do świerzbu. ¹

Rokowanie w świerzbie (Prognosis)

Ogólnie można stwierdzić, że przy odpowiednim leczeniu rokowanie w przypadku świerzbu jest dobre. Leczenie pacjenta wraz z bliskimi kontaktami i członkami rodziny jest związane z dobrym rokowaniem. Przy właściwym leczeniu można oczekiwać pełnego wyzdrowienia pacjentów. ³ Natomiast bez leczenia zakażenie może rozprzestrzenić się na innych członków społeczności i spowodować ognisko epidemiczne w populacji. ³

Skuteczność leczenia i ocena wyleczenia

Pomyślny wynik leczenia powinien być oczekiwany w ciągu około dwóch tygodni. ⁴ Objawy choroby zazwyczaj ustępują w tym czasie, jednak kluczowe dla rokowania jest przeprowadzenie kontroli po leczeniu, aby ocenić wyleczenie pacjenta i zapobiec ponownej inwazji. ⁴

Badania dotyczące skuteczności różnych metod leczenia wskazują na zróżnicowane wyniki. Na przykład, w jednym z badań po 4 tygodniach, iwermektyna miała wskaźnik wyleczenia na poziomie 78,5% przy podaniu pojedynczej dawki, podczas gdy 59,5% pacjentów dobrze zareagowało na pojedyncze leczenie 10% maścią siarkową. ⁵

Przyczyny niepowodzeń terapeutycznych

Niepowodzenia leczenia są obserwowane głównie dlatego, że leki nie są w 100% skuteczne. ⁶ Przyczyny pozornego niepowodzenia leczenia skutecznym preparatem obejmują:

Nieprawidłową diagnozę
Zapalenie skóry wtórne do obecności roztocza lub zastosowanego środka miejscowego
Nieprawidłowe stosowanie środka miejscowego
Słabą penetrację środka do hiperkeratotycznej skóry lub paznokci
Ponowne zakażenie od bliskich kontaktów zarażonych świerzbem ⁶

Wpływ świerzbu na jakość życia

Dyskomfort spowodowany intensywnym świądem może mieć bezpośrednie konsekwencje, tj. pozbawianie pacjentów snu, zaburzanie koncentracji w pracy lub szkole, prowadząc do negatywnego wpływu na frekwencję, wydajność i jakość życia. ⁴

Wszystkie analizowane badania wykazały znaczący wpływ diagnozy świerzbu na jakość życia pacjentów. ⁷ Wyniki wskazują na istotną korelację między świerzbem a obniżoną jakością życia. ⁷

Niektórzy badacze zaobserwowali umiarkowany do silnego wpływ na jakość życia, podczas gdy inni zidentyfikowali istotny związek między świerzbem a lękiem/depresją, co dodatkowo pogarsza jakość życia. ⁸ Biorąc pod uwagę, że badania opisują upośledzenie jakości życia jako bardzo duże, rośnie potrzeba leczenia objawów i zapewnienia kompleksowej i skutecznej opieki. ⁹

Perspektywy w zwalczaniu świerzbu

Skuteczność programów profilaktycznych

Badania pokazują, że programy profilaktyki i leczenia świerzbu wprowadzone na początku procedury azylowej są wykonalne i skuteczne, jak wykazano w Holandii. Dzięki takim programom pacjenci są wcześnie diagnozowani, a ryzyko ponownych zarażeń i powikłań ulega zmniejszeniu. ¹⁰

W rezultacie wprowadzenia takiego programu zmniejszyła się liczba ponownych zarażeń świerzbem po leczeniu oraz liczba powikłanych form świerzbu. ¹¹ Wprowadzenie programu skutecznie zapobiegało wybuchom ognisk świerzbu. ¹²

Innowacje w leczeniu

Ogólnoświatowa częstość występowania świerzbu pozostaje wysoka, a obecnie dostępne metody leczenia mogą nie być wystarczająco skuteczne, aby kontrolować chorobę. ⁶ Dlatego poprawa w zarządzaniu świerzbem jest niezbędna i będzie wynikać z lepszej identyfikacji pacjentów wymagających leczenia. ⁴

Istotnym krokiem w kierunku poprawy leczenia świerzbu są badania nad dostosowaniem dawkowania leków dla młodszych grup wiekowych. Na przykład, iwermektyna jest obecnie licencjonowana w Australii do stosowania u dzieci w wieku pięciu lub więcej lat i o wadze powyżej 15 kg. Jednak małe dzieci w wieku poniżej pięciu lat są narażone na wysokie ryzyko zarażenia świerzbem i jego wtórnych powikłań. ¹³

W związku z tym przeprowadzono prospektywne badanie farmakokinetyczne w celu opracowania populacyjnego modelu farmakokinetycznego iwermektyny u dzieci, u których lek jest obecnie licencjonowany. Model ten wykorzystano do symulacji odpowiedniej dawki dla dzieci w wieku od dwóch do czterech lat i ważących mniej niż 15 kg. ¹³ Badanie to zidentyfikowało strategię dawkowania (tj. dawkę 3 mg) dla dzieci w wieku od 2 do 4 lat, która zapewnia ekspozycję na lek porównywalną do ekspozycji u dzieci w wieku powyżej 4 lat. ¹⁴

Perspektywy na przyszłość

Zarządzanie świerzbem pozostaje w dużej mierze suboptymalne, od diagnozy po leczenie, a postęp w rozwoju nowych środków terapeutycznych prowadzących do wyleczenia jest pilnie potrzebny. ¹ Istnieje nadzieja, że kolejne 10 lat przyniesie znaczącą poprawę dla pacjentów zarażonych świerzbem, a nowe leki i metody diagnostyczne poszerzą opcje terapeutyczne z korzyścią dla pacjentów i ich rodzin. ⁶

Dokładna i definitywna diagnoza świerzbu ma kluczowe znaczenie dla poprawy rokowania. ⁴ Ciągłe badania nad nowymi metodami leczenia, takimi jak symulowana dawka 3 mg iwermektyny dla dzieci w wieku od 2 do 4 lat o wadze od 10 do 15 kg, mogą być w przyszłości ocenione pod kątem bezpieczeństwa i skuteczności. ¹⁵

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 The Management of Scabies in the 21st Century: Past, Advances and Potentials
https://pmc.ncbi.nlm.nih.gov/articles/PMC9128908/
Scabies is one of the most common skin diseases worldwide, affecting 150200 million people yearly. […] The burden of the disease is now well characterized, including group A Streptococcus and Staphylococcus aureus bacterial superinfections, with reports of nephritis, acute rheumatic fever, or fatal invasive sepsis secondary to scabies. […] Management of scabies remains largely suboptimal from diagnosis to treatment, and progress in the development of new therapeutic measures leading to cure is urgently needed. […] Scabies is a prevalent disease, which is present in all parts of the world, with greatest prominence in disadvantaged populations living in tropical and subtropical regions, and has a documented significant burden. […] For a long time, the scabies mite has been erroneously perceived as an ectoparasite that just causes itching. However, recent epidemiological studies indicate increasingly substantial morbidity, and even mortality due to scabies infection, mostly caused by bacterial infections appearing with the parasitic infestation.
#2 Impact of Scabies on Quality of Life and Recent Advances in Management: A Systematic Review | medRxiv
https://www.medrxiv.org/content/10.1101/2024.11.25.24317899v1.full-text
Scabies most commonly affect children of lower socioeconomic status and in resource-limited settings. […] Findings indicate a significant correlation between scabies and poor quality of life. […] Scabies significantly lower a patients quality of life. […] A study shows At the 4-week mark, Ivermectin had a cure rate of 78.5% with a single dose, whereas 59.5% of patients responded well to a single treatment of 10% sulfur ointment. […] All 22 studies demonstrated a significant impact of scabies diagnosis and quality of life on the participants. […] Ko Yldrm S et al. observed a moderate to severe effect on the quality of life, while Khaled Seetan et al. identified a significant association between scabies and anxiety/depression, further compromising the quality of life. […] Our study concluded that scabies is a debilitating disease with a significant impact on quality of life. […] With studies describing the impairment of QoL as being very large, the need to address the symptoms and provide complete and effective care is rising.
#3 Scabies – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK544306/
Treating the patient along with close contacts and family members is associated with a good prognosis. With adequate treatment, patients can be expected to recover fully. […] Without treatment, the infection can spread to other members of the community and cause an outbreak within the population.
#4 The Management of Scabies in the 21st Century: Past, Advances and Potentials
https://pmc.ncbi.nlm.nih.gov/articles/PMC9128908/
The discomfort caused by the intense itch can have direct consequences, i.e. depriving patients of sleep, interfering with concentration at work or school, leading to a negative impact on attendance, performance and quality of life. […] This association between scabies parasites and bacterial pathogens is observed mainly in tropical or subtropical areas of the globe and in remote locations; with some data suggesting that up to 40% of impetigo lesions can be linked with scabies, especially among young children. […] Improvement in scabies management is essential and will come from better identification of which patients need to be treated. Thus, the accurate and definitive diagnosis of scabies is crucial. […] Follow-up is necessary after treatment, to evaluate the cure of the patient and to prevent re-infestation. Treatment success should be expected in approximately two weeks.
#5 Impact of Scabies on Quality of Life and Recent Advances in Management: A Systematic Review | medRxiv
https://www.medrxiv.org/content/10.1101/2024.11.25.24317899v1.full-text
Scabies most commonly affect children of lower socioeconomic status and in resource-limited settings. […] Findings indicate a significant correlation between scabies and poor quality of life. […] Scabies significantly lower a patients quality of life. […] A study shows At the 4-week mark, Ivermectin had a cure rate of 78.5% with a single dose, whereas 59.5% of patients responded well to a single treatment of 10% sulfur ointment. […] All 22 studies demonstrated a significant impact of scabies diagnosis and quality of life on the participants. […] Ko Yldrm S et al. observed a moderate to severe effect on the quality of life, while Khaled Seetan et al. identified a significant association between scabies and anxiety/depression, further compromising the quality of life. […] Our study concluded that scabies is a debilitating disease with a significant impact on quality of life. […] With studies describing the impairment of QoL as being very large, the need to address the symptoms and provide complete and effective care is rising.
#6 The Management of Scabies in the 21st Century: Past, Advances and Potentials
https://pmc.ncbi.nlm.nih.gov/articles/PMC9128908/
Causes of apparent treatment failure with an effective treatment include incorrect diagnosis, dermatitis secondary to the mite or topical agent, incorrect application of the topical agent, poor penetration of the agent into hyperkeratotic skin or nails, and re-infestation from scabies-infested close contacts. […] Treatment failure has been observed, mainly because drugs are not 100% effective. […] The worldwide prevalence of scabies remains high, and currently available treatments may not be sufficiently effective to control the disease. […] We hope that the next 10 years will provide a significant improvement for patients infested with scabies, and that new drugs and diagnostics will enhance the therapeutic options for the benefit of patients and their families.
#7 Impact of Scabies on Quality of Life and Recent Advances in Management: A Systematic Review | medRxiv
https://www.medrxiv.org/content/10.1101/2024.11.25.24317899v1.full-text
Scabies most commonly affect children of lower socioeconomic status and in resource-limited settings. […] Findings indicate a significant correlation between scabies and poor quality of life. […] Scabies significantly lower a patients quality of life. […] A study shows At the 4-week mark, Ivermectin had a cure rate of 78.5% with a single dose, whereas 59.5% of patients responded well to a single treatment of 10% sulfur ointment. […] All 22 studies demonstrated a significant impact of scabies diagnosis and quality of life on the participants. […] Ko Yldrm S et al. observed a moderate to severe effect on the quality of life, while Khaled Seetan et al. identified a significant association between scabies and anxiety/depression, further compromising the quality of life. […] Our study concluded that scabies is a debilitating disease with a significant impact on quality of life. […] With studies describing the impairment of QoL as being very large, the need to address the symptoms and provide complete and effective care is rising.
#8 Impact of Scabies on Quality of Life and Recent Advances in Management: A Systematic Review | medRxiv
https://www.medrxiv.org/content/10.1101/2024.11.25.24317899v1.full-text
Scabies most commonly affect children of lower socioeconomic status and in resource-limited settings. […] Findings indicate a significant correlation between scabies and poor quality of life. […] Scabies significantly lower a patients quality of life. […] A study shows At the 4-week mark, Ivermectin had a cure rate of 78.5% with a single dose, whereas 59.5% of patients responded well to a single treatment of 10% sulfur ointment. […] All 22 studies demonstrated a significant impact of scabies diagnosis and quality of life on the participants. […] Ko Yldrm S et al. observed a moderate to severe effect on the quality of life, while Khaled Seetan et al. identified a significant association between scabies and anxiety/depression, further compromising the quality of life. […] Our study concluded that scabies is a debilitating disease with a significant impact on quality of life. […] With studies describing the impairment of QoL as being very large, the need to address the symptoms and provide complete and effective care is rising.
#9 Impact of Scabies on Quality of Life and Recent Advances in Management: A Systematic Review | medRxiv
https://www.medrxiv.org/content/10.1101/2024.11.25.24317899v1.full-text
Scabies most commonly affect children of lower socioeconomic status and in resource-limited settings. […] Findings indicate a significant correlation between scabies and poor quality of life. […] Scabies significantly lower a patients quality of life. […] A study shows At the 4-week mark, Ivermectin had a cure rate of 78.5% with a single dose, whereas 59.5% of patients responded well to a single treatment of 10% sulfur ointment. […] All 22 studies demonstrated a significant impact of scabies diagnosis and quality of life on the participants. […] Ko Yldrm S et al. observed a moderate to severe effect on the quality of life, while Khaled Seetan et al. identified a significant association between scabies and anxiety/depression, further compromising the quality of life. […] Our study concluded that scabies is a debilitating disease with a significant impact on quality of life. […] With studies describing the impairment of QoL as being very large, the need to address the symptoms and provide complete and effective care is rising.
#10 Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 â March 2016 | PLOS Neglected Tropical Diseases
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006401
Scabies is a skin infestation with the mite Sarcoptes scabiei causing itch and rash and is a major risk factor for bacterial skin infections and severe complications. […] A scabies prevention and treatment programme at start of the asylum procedure was feasible and effective in the Netherlands; patients were diagnosed early and risk of reinfestations and complications reduced. […] This study shows that a scabies prevention and treatment programme at start of the asylum procedure is feasible and effective in the Netherlands. Patients were diagnosed early and risk of reinfestations and complications reduced. […] The number of scabies reinfestations after treatment and the number of complicated forms of scabies reduced after introduction of the programme. […] Introduction of the SIP was effective in the prevention of scabies outbreaks. […] The introduction of the programme reduced the number and the severity of the complicated forms of scabies.
#11 Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 â March 2016 | PLOS Neglected Tropical Diseases
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006401
Scabies is a skin infestation with the mite Sarcoptes scabiei causing itch and rash and is a major risk factor for bacterial skin infections and severe complications. […] A scabies prevention and treatment programme at start of the asylum procedure was feasible and effective in the Netherlands; patients were diagnosed early and risk of reinfestations and complications reduced. […] This study shows that a scabies prevention and treatment programme at start of the asylum procedure is feasible and effective in the Netherlands. Patients were diagnosed early and risk of reinfestations and complications reduced. […] The number of scabies reinfestations after treatment and the number of complicated forms of scabies reduced after introduction of the programme. […] Introduction of the SIP was effective in the prevention of scabies outbreaks. […] The introduction of the programme reduced the number and the severity of the complicated forms of scabies.
#12 Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 â March 2016 | PLOS Neglected Tropical Diseases
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006401
Scabies is a skin infestation with the mite Sarcoptes scabiei causing itch and rash and is a major risk factor for bacterial skin infections and severe complications. […] A scabies prevention and treatment programme at start of the asylum procedure was feasible and effective in the Netherlands; patients were diagnosed early and risk of reinfestations and complications reduced. […] This study shows that a scabies prevention and treatment programme at start of the asylum procedure is feasible and effective in the Netherlands. Patients were diagnosed early and risk of reinfestations and complications reduced. […] The number of scabies reinfestations after treatment and the number of complicated forms of scabies reduced after introduction of the programme. […] Introduction of the SIP was effective in the prevention of scabies outbreaks. […] The introduction of the programme reduced the number and the severity of the complicated forms of scabies.
#13 Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children | PLOS Neglected Tropical Diseases
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008886
Ivermectin is currently licensed in Australia for use in children aged five or more years and weighing greater than 15 kg. However, young children aged less than five years are at high risk of scabies infestation and its secondary complications. […] Therefore, in this study we conducted a prospective pharmacokinetic study to develop a population pharmacokinetic model of ivermectin in children in whom the drug is currently licensed and used the model to simulate an appropriate dose for children aged between two and four years and weighing less than 15 kg. […] This study identified a dosing strategy (i.e. a dose of 3 mg) for children aged 2 to 4 years that achieves comparable drug exposure to children aged over 4 years. […] We propose that our simulated dose of 3 mg can now be prospectively evaluated to determine safety and efficacy in children aged 2 to 4 years and weighing 10 to 15 kg.
#14 Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children | PLOS Neglected Tropical Diseases
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008886
Ivermectin is currently licensed in Australia for use in children aged five or more years and weighing greater than 15 kg. However, young children aged less than five years are at high risk of scabies infestation and its secondary complications. […] Therefore, in this study we conducted a prospective pharmacokinetic study to develop a population pharmacokinetic model of ivermectin in children in whom the drug is currently licensed and used the model to simulate an appropriate dose for children aged between two and four years and weighing less than 15 kg. […] This study identified a dosing strategy (i.e. a dose of 3 mg) for children aged 2 to 4 years that achieves comparable drug exposure to children aged over 4 years. […] We propose that our simulated dose of 3 mg can now be prospectively evaluated to determine safety and efficacy in children aged 2 to 4 years and weighing 10 to 15 kg.
#15 Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children | PLOS Neglected Tropical Diseases
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008886
Ivermectin is currently licensed in Australia for use in children aged five or more years and weighing greater than 15 kg. However, young children aged less than five years are at high risk of scabies infestation and its secondary complications. […] Therefore, in this study we conducted a prospective pharmacokinetic study to develop a population pharmacokinetic model of ivermectin in children in whom the drug is currently licensed and used the model to simulate an appropriate dose for children aged between two and four years and weighing less than 15 kg. […] This study identified a dosing strategy (i.e. a dose of 3 mg) for children aged 2 to 4 years that achieves comparable drug exposure to children aged over 4 years. […] We propose that our simulated dose of 3 mg can now be prospectively evaluated to determine safety and efficacy in children aged 2 to 4 years and weighing 10 to 15 kg.